User menu

In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units.

Bibliographic reference Glupczynski, Gerald ; Huang, Te-Din ; Berhin, C. ; Claeys, G. ; Delmée, Michel ; et. al. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units.. In: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, Vol. 26, no. 11, p. 777-83 (2007)
Permanent URL http://hdl.handle.net/2078.1/24964
  1. Slocombe B, Cooper CE, Griffin KE, White AR (1985) Temocillin: in vitro antibacterial activity. Drugs 29(Suppl 5):49–56
  2. Van Landuyt H, Boelaert J, Piot P, Verbist L (1985) In vitro activity of temocillin against clinical isolates. Drugs 29(Suppl 5):1–8
  3. Spencer RC (1990) Temocillin. J Antimicrob Chemother 26:735–737
  4. Taylor RF, Gaya H, Hodson ME (1992) Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia. J Antimicrob Chemother 29:341–344
  5. Lekkas A, Gyi KM, Hodson ME (2006) Temocillin in the treatment of Burkholderia cepacia infections in cystic fibrosis. J Cyst Fibros 5:121–124
  6. Vanhoof R., Bérin C., Carpentier M., Fagnart O., Glupczynski Y., Mans I., Nyssen H.-J., Surmont I., Van Nimmen L., COMPARATIVEIN VITROACTIVITY OF TEMOCILLIN AND OTHER ANTIMICROBIAL AGENTS AGAINST ENTEROBACTERIACEAE ISOLATED FROM PATIENTS ADMITTED TO FIVE BELGIAN HOSPITALS, 10.1179/acb.2001.053
  7. Rodriguez-Villalobos H, Malaviolle V, Frankard J, de Mendonça R, Nonhoff C, Struelens MJ (2006) In vitro activity of temocillin against extended spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 57:771–774
  8. Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57:1012–1014
  9. Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing. Approved standard MS100-S16. CLSI, Wayne, PA, USA
  10. Fuchs PC, Barry AL, Thornsberry C, Jones RN (1985) Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol 4:30–33
  11. Stürenburg E, Sobottka I, Noor D, Laufs R, Mack D (2004) Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum β-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother 54:134–138
  12. De Gheldre Y, Avesani V, Berhin C, Delmee M, Glupczynski Y (2003) Evaluation of Oxoid combination discs for detection of extended-spectrum β-lactamases. J Antimicrob Chemother 52:591–597
  13. De Gheldre Y, Glupczynski Y, Berhin C et al (2004) Epidemiology of Enterobacter aerogenes in Belgium: results of a multicentre survey. In: Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases. Abstract no. P-1122. Clin Microbiol Infect 10(Suppl 3):305 (abstract)
  14. De Gheldre Y, Struelens MJ, Glupczynski Y, et al (2001) National epidemic surveys of Enterobacter aerogenes in Belgian hospitals from 1996 to 1998. J Clin Microbiol 39:889–896
  15. Glupczynski Y., Delmée M., Goossens H., Struelens M., , DISTRIBUTION AND PREVALENCE OF ANTIMICROBIAL RESISTANCE AMONG GRAM-NEGATIVE ISOLATES IN INTENSIVE CARE UNITS (ICU) IN BELGIAN HOSPITALS BETWEEN 1996 AND 1999, 10.1179/acb.2001.044
  16. Ieven M, Delmee M, De Mol P et al (2006) Eight years of Belgian MYSTIC surveillance: 1998–2005. In: Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 2006, Abstract no. P-1387
  17. Rodriguez-Villalobos H, Malaviolle V, Frankard J et al (2005) Emergence of CTX-M extended-spectrum β-lactamase-producing Escherichia coli in Belgium. Euro-surveillance Weekly 10:63. Available online: ( http://www.eurosurveillance.org/ew/2005/050224.asp#3 )